In the near future, clinical studies employing BTK-inhibitors as treatments for CLL-related AICs will manage to cast new light on their potential role as an earlier therapy line for these conditions and phase II trials using these inhibitors (with or without rituximab) are currently ongoing in CLL-wAIHA (NCT03827603) and ITP (NCT03395210). The gene discussed is BTK; the disease is autoimmune thrombocytopenic purpura.